Skip to content
Search for...
Lyhyesti suomeksi
Contact Us
Home
Investors
Why Invest?
Reports and presentations
Corporate Governance
Articles of Association
General Meetings
Board of Directors
Management
Auditor
Press Releases
Investor Relations
Technology
Traumatic Brain Injury
Biomarker R&D program
Proof of concept
Second clinical study
Third clinical study
Assay development plan
Drug development program
IP Rights
Company Profile
Letter From Our CEO
Business Strategy
Board of Directors
Management
Team
News & Events
Press Releases
Lehdistötiedotteet
Articles
Videos
Search for...
Contact Us
Lyhyesti suomeksi
Navigation Menu
Navigation Menu
Home
Investors
Why Invest?
Reports and presentations
Corporate Governance
Articles of Association
General Meetings
Board of Directors
Management
Auditor
Press Releases
Investor Relations
Technology
Traumatic Brain Injury
Biomarker R&D program
Proof of concept
Second clinical study
Third clinical study
Assay development plan
Drug development program
IP Rights
Company Profile
Letter From Our CEO
Business Strategy
Board of Directors
Management
Team
News & Events
Press Releases
Lehdistötiedotteet
Articles
Videos
Uncategorized
Medicortex’s representative at Life Sciences Baltics event
17.9.2025
Medicortex has a share issue until 10.9.2025
2.9.2025
2.9.2025
Turun Sanomat published about Medicortex
29.8.2025
29.8.2025
Medicortex was granted an Israeli patent for non-invasive TBI diagnostics
28.8.2025
28.8.2025
Nosium AB (publ) writes about Medicortex
31.7.2025
31.7.2025
Medicortex signed a Letter of Intent with Nosium AB (publ)
25.6.2025
25.6.2025
Annual General Meeting // Varsinainen yhtiökokous
20.3.2025
20.3.2025
Share Issue Until 18.02.2025
5.2.2025
5.2.2025
Medicortex’s Share Issue 28.10-11.11.2024
28.10.2024
28.10.2024
Preparations for listing ongoing
23.10.2024
23.10.2024
1
2
3
Seuraava »